Anne Langsted1, Anette Varbo1, Pia R Kamstrup1, Børge G Nordestgaard1. 1. Department of Clinical Biochemistry (A.L., A.V., P.R.K., B.G.N.), and The Copenhagen General Population Study (A.L., A.V., P.R.K., B.G.N.), Herlev Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; The Copenhagen City Heart Study (B.G.N.), Frederiksberg Hospital, Copenhagen University Hospital, 2000 Frederiksberg, Denmark; and Faculty of Health and Medical Sciences (A.L., A.V., P.R.K., B.G.N.), University of Copenhagen, 1165 Copenhagen, Denmark.
Abstract
CONTEXT: It is unknown whether elevated lipoprotein(a) is causally associated with low-grade inflammation. OBJECTIVE: We tested the hypothesis that elevated lipoprotein(a) is observationally and causally associated with low-grade inflammation together with aortic valve stenosis and myocardial infarction. DESIGN AND SETTING: Using a multidirectional Mendelian randomization approach, we studied 100,578 individuals from the Danish general population with plasma levels of and/or genotypes known to affect levels of lipoprotein(a) and C-reactive protein (CRP), and using information regarding diagnosis of aortic valve stenosis and of myocardial infarction (MI) from registries. RESULTS: Observationally, CRP increased by 29% (95% confidence interval [CI], 23-34) per 50-mg/dL increase in lipoprotein(a). However, two LPA single nucleotide polymorphisms (SNPs) and the kringle IV type 2 (KIV-2) genotype that were associated with 98, 95, and 68 mg/dL higher lipoprotein(a) levels were not causally associated with increased CRP levels. For aortic valve stenosis, a 1-SD increase in lipoprotein(a) levels was associated observationally with a multifactorially adjusted hazard ratio of 1.23 (95% CI, 1.06-1.41), with corresponding causal risk ratios of 1.38 (1.23-1.55) based on LPA SNPs and of 1.21 (1.06-1.40) based on LPA KIV-2 genotype. For myocardial infarction, corresponding values were 1.20 (1.10;1.31) observationally, and 1.18 (1.11;1.26) and 1.31 (1.22;1.42) causally, respectively. Observational hazard ratios for aortic valve stenosis and MI were similar after further adjustment for CRP levels. CONCLUSIONS: Elevated levels of lipoprotein(a) were not causally associated with increased low-grade inflammation as measured through CRP despite a causal association with increased risk of aortic valve stenosis and MI.
CONTEXT: It is unknown whether elevated lipoprotein(a) is causally associated with low-grade inflammation. OBJECTIVE: We tested the hypothesis that elevated lipoprotein(a) is observationally and causally associated with low-grade inflammation together with aortic valve stenosis and myocardial infarction. DESIGN AND SETTING: Using a multidirectional Mendelian randomization approach, we studied 100,578 individuals from the Danish general population with plasma levels of and/or genotypes known to affect levels of lipoprotein(a) and C-reactive protein (CRP), and using information regarding diagnosis of aortic valve stenosis and of myocardial infarction (MI) from registries. RESULTS: Observationally, CRP increased by 29% (95% confidence interval [CI], 23-34) per 50-mg/dL increase in lipoprotein(a). However, two LPA single nucleotide polymorphisms (SNPs) and the kringle IV type 2 (KIV-2) genotype that were associated with 98, 95, and 68 mg/dL higher lipoprotein(a) levels were not causally associated with increased CRP levels. For aortic valve stenosis, a 1-SD increase in lipoprotein(a) levels was associated observationally with a multifactorially adjusted hazard ratio of 1.23 (95% CI, 1.06-1.41), with corresponding causal risk ratios of 1.38 (1.23-1.55) based on LPA SNPs and of 1.21 (1.06-1.40) based on LPA KIV-2 genotype. For myocardial infarction, corresponding values were 1.20 (1.10;1.31) observationally, and 1.18 (1.11;1.26) and 1.31 (1.22;1.42) causally, respectively. Observational hazard ratios for aortic valve stenosis and MI were similar after further adjustment for CRP levels. CONCLUSIONS: Elevated levels of lipoprotein(a) were not causally associated with increased low-grade inflammation as measured through CRP despite a causal association with increased risk of aortic valve stenosis and MI.
Authors: Hao Yu Chen; Line Dufresne; Hannah Burr; Athithan Ambikkumar; Niko Yasui; Kevin Luk; Dilrini K Ranatunga; Rachel A Whitmer; Mark Lathrop; James C Engert; George Thanassoulis Journal: JAMA Cardiol Date: 2018-01-01 Impact factor: 14.676
Authors: Pia R Kamstrup; Ming-Yow Hung; Joseph L Witztum; Sotirios Tsimikas; Børge G Nordestgaard Journal: Arterioscler Thromb Vasc Biol Date: 2017-06-01 Impact factor: 8.311
Authors: Jing Cao; Brian T Steffen; Matthew Budoff; Wendy S Post; George Thanassoulis; Bryan Kestenbaum; Joseph P McConnell; Russell Warnick; Weihua Guan; Michael Y Tsai Journal: Arterioscler Thromb Vasc Biol Date: 2016-03-03 Impact factor: 8.311
Authors: Hao Yu Chen; Benjamin J Cairns; Aeron M Small; Hannah A Burr; Athithan Ambikkumar; Andreas Martinsson; Sébastien Thériault; Hans Markus Munter; Brian Steffen; Richard Zhang; Rebecca T Levinson; Christian M Shaffer; Jian Rong; Emily Sonestedt; Line Dufresne; Johan Ljungberg; Ulf Näslund; Bengt Johansson; Dilrini K Ranatunga; Rachel A Whitmer; Matthew J Budoff; Albert Nguyen; Ramachandran S Vasan; Martin G Larson; William S Harris; Scott M Damrauer; Ken D Stark; S Matthijs Boekholdt; Nicholas J Wareham; Philippe Pibarot; Benoit J Arsenault; Patrick Mathieu; Vilmundur Gudnason; Christopher J O'Donnell; Jerome I Rotter; Michael Y Tsai; Wendy S Post; Robert Clarke; Stefan Söderberg; Yohan Bossé; Quinn S Wells; J Gustav Smith; Daniel J Rader; Mark Lathrop; James C Engert; George Thanassoulis Journal: JAMA Cardiol Date: 2020-06-01 Impact factor: 30.154